Calithera Biosciences, Inc.
Calithera Biosciences, Inc. (CALA): 11 pipeline candidates · ~9 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.1 months
D/E 0.41 · 0% dilution
Lead: Phase 2
11 candidates
N/A
N/A
A transparent, data-derived signal for Calithera Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1K
Cash
$25.7M
Quarterly Burn
$8.6M
Runway
9.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| cala one | — |
| CB-280 | Phase 1 |
| CB-668 | Preclinical |
| CB-708 (ATG-037) | Phase 1 |
| INCB001158 | Phase 1 |
| Mivavotinib (CB-659, formerly TAK-659) | Phase 2 |
| Mivavotinib (CB-659) | Phase 2 |
| Sapanisertib (CB-228, formerly TAK-228) | Phase 2 |
| Sapanisertib (CB-228) | Phase 2 |
| Telaglenastat (CB-839) | Phase 2 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Sep 2025Institutional holders
1
Total value held
$0
| Holder | Shares | Value |
|---|---|---|
| ameriflex group, inc. | 36 | $0 |
Frequently asked questions
How many drug candidates are in Calithera Biosciences, Inc.'s pipeline?
Calithera Biosciences, Inc. (CALA) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Calithera Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Calithera Biosciences, Inc. has approximately 9.1 months of cash runway.
What is Calithera Biosciences, Inc.'s market capitalization?
Calithera Biosciences, Inc.'s market capitalization is approximately $1K.
Who is the CEO of Calithera Biosciences, Inc.?
Chief Executive Officer is the chief executive officer of Calithera Biosciences, Inc. (CALA).
Get the full picture on Calithera Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.